Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Expanding from generics to biosimilars in India

The first biosimilar in India was approved in 2000, and, with the help of legislation and regulation from the Indian Government, the market has continued to grow since, reaching a value of $2.2bn in 2017. However, biosimilars remain challenging to manufacture for Indian pharmaceutical companies, at the emerging end of the market.

Go Top